COVID-19 is not a driver of clinically significant viral wheeze and asthma

At the start of the school year, there is an influx of children with attacks of viral wheeze and asthma who present to children’s emergency departments. In the UK, the COVID-19 pandemic has resulted in extensive school lockdowns and the implementation of social distancing measures within schools. We aimed to determine the extent that SARS-CoV-2 has been identified in children admitted to hospital with viral wheeze and/or asthma at the start of the 2020 school year and compare presentation trends to previous years. Leicester was the first city in the UK to have a geographically specific lockdown imposed on it due to higher than average rates of SARS-CoV-2 infection per population size.

We compared 4 years, 2017–2020, and extracted data on presentations to, and admissions from, our tertiary children’s emergency department (pre-COVID-19 attendances were 60000 per year) for the first 4 weeks of the school year (table 1). An admission was defined as a decision to admit to a hospital or short stay bed. In accordance with government guidance, only children who are admitted to hospital receive SARS-CoV-2 swabs. The evaluation was registered with the hospital audit and improvement committee (10786).

In 2020, there were no positive SARS-CoV-2 samples in children admitted with attacks of viral wheeze or asthma during the start of the school year. Our data would indicate, in our locality, SARS-CoV-2 is not playing a role in the annual spike in viral wheeze and asthma admissions. There is a risk of a type 2 error of interpretation due to the relatively small sample size, but the complete absence of positive results lead us to believe this is unlikely. Our department has previously demonstrated an overall very low rate of SARS-CoV-2 in admitted children that would support these findings. Our conclusion also presumes a similar asthma severity phenotype each year that we believe is a reasonable assumption due to the very similar numbers of presentations and outcomes across years.

<table>
<thead>
<tr>
<th>Time frame</th>
<th>Presentations</th>
<th>Admitted (%)</th>
<th>Intensive care admissions</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017 (23/8–20/9)</td>
<td>187</td>
<td>123 (65.7)</td>
<td>1</td>
</tr>
<tr>
<td>2018 (30/8–27/9)</td>
<td>290</td>
<td>187 (64.5)</td>
<td>3</td>
</tr>
<tr>
<td>2019 (29/8–26/9)</td>
<td>229</td>
<td>139 (60.7)</td>
<td>2</td>
</tr>
<tr>
<td>2020 (24/8–21/9)</td>
<td>237</td>
<td>133 (56.1)</td>
<td>1</td>
</tr>
</tbody>
</table>

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; internally peer reviewed.

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

To cite Roland D, Teo KW, Bandi S, et al. Arch Dis Child Epub ahead of print: [please include Day Month Year]. doi:10.1136/archdischild-2020-320776

Accepted 9 October 2020

Arch Dis Child 2020;0:1.

doi:10.1136/archdischild-2020-320776

ORCID iD

Damian Roland http://orcid.org/0000-0001-9334-5144

REFERENCES
